These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 7448733)

  • 41. Prognostic significance of estrogen and progesterone receptors in stage II breast cancer.
    Rydén S; Fernö M; Borg A; Hafström L; Möller T; Norgren A
    J Surg Oncol; 1988 Apr; 37(4):221-6. PubMed ID: 3283457
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estrogen receptor-negative progesterone receptor-positive breast cancer - "Nobody's land" or just an artifact?
    Kunc M; Biernat W; Senkus-Konefka E
    Cancer Treat Rev; 2018 Jun; 67():78-87. PubMed ID: 29772460
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer.
    Young PC; Ehrlich CE; Einhorn LH
    Cancer; 1980 Dec; 46(12 Suppl):2961-3. PubMed ID: 7448744
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estrogen and progesterone receptors in the prediction of response of breast cancer to endocrine therapy.
    Manni A; Arafah B; Pearson OH
    Cancer; 1980 Dec; 46(12 Suppl):2838-41. PubMed ID: 7448730
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors.
    Moseley HS; Peetz ME; Keenan EJ; Awrich AE; Fletcher WS
    Am J Surg; 1980 Jul; 140(1):164-72. PubMed ID: 7396080
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
    Olsson H; Borg A; Ewers SB; Fernö M; Möller T; Ranstam J
    Med Oncol Tumor Pharmacother; 1986; 3(2):77-81. PubMed ID: 3747639
    [TBL] [Abstract][Full Text] [Related]  

  • 50. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of histo- and biochemical methods for estrogen and progesterone receptor analysis in primary human breast carcinoma.
    Paulsen SM; Pedersen KO
    Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1331-6. PubMed ID: 4076294
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.
    Fernö M; Stål O; Baldetorp B; Hatschek T; Källström AC; Malmström P; Nordenskjöld B; Rydën S
    Breast Cancer Res Treat; 2000 Jan; 59(1):69-76. PubMed ID: 10752681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concordance and discordance of estrogen and progesterone receptor content in sequential biopsies of patients with advanced breast cancer: relation to survival.
    Raemaekers JM; Beex LV; Koenders AJ; Pieters GF; Smals AG; Benraad TJ; Kloppenborg PW
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1011-8. PubMed ID: 6540683
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical Characteristics and Outcomes of Single Versus Double Hormone Receptor-Positive Breast Cancer in 2 Large Databases.
    Li Z; Tu Y; Wu Q; Wang Z; Li J; Zhang Y; Sun S
    Clin Breast Cancer; 2020 Apr; 20(2):e151-e163. PubMed ID: 31551181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factors associated with prognosis in human breast cancer. V. The simultaneous use of estrogen and progesterone receptor measurements for prediction of short-term relapse.
    Pascual MR; Macías A; Moreno L; Lage A
    Neoplasma; 1985; 32(2):247-56. PubMed ID: 4000312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histochemical assay of estrogen and progesterone receptors in breast cancer: correlation with biochemical assays and patients' response to endocrine therapies.
    Pertschuk LP; Tobin EH; Gaetjens E; Carter AC; Degenshein GA; Bloom ND; Brigati DJ
    Cancer; 1980 Dec; 46(12 Suppl):2896-901. PubMed ID: 6256056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival.
    Pertschuk LP; Kim DS; Nayer K; Feldman JG; Eisenberg KB; Carter AC; Rong ZT; Thelmo WL; Fleisher J; Greene GL
    Cancer; 1990 Oct; 66(8):1663-70. PubMed ID: 2208020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progesterone receptors and human breast cancer.
    Clark GM; McGuire WL
    Breast Cancer Res Treat; 1983; 3(2):157-63. PubMed ID: 6351950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.